Protalix BioTherapeutics (PLX) Misses Q2 EPS by 17c

Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.25), $0.17 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $6.43 million versus the consensus estimate of $8.3 million.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Benchmark Reiterates Buy Rating on H World Group Ltd. (HTHT) Following Q2 Print
• Raymond James sees positive earnings trends across market caps